SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is trending as a U.S. House investigation into its $500 million investment deal with a UAE royal ignites a polarized community debate over its political implications and financial integrity. While proponents view the scrutiny as a buying opportunity ahead of anticipated product launches, skeptics dismiss the Trump-linked crypto venture as a "scam," fueling conversations around crypto regulation and market intervention.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to its FDA Breakthrough Device Designation for the CellFX nsPFA Cardiac Surgery System and positive clinical data from first-in-human studies. The community is actively discussing the game-changing potential of its nanosecond Pulsed Field Ablation platform technology across multiple medical applications, reinforced by notable insider buying.

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical, Risk, Legal Exhibitions and Print & print-related. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. The Risk segment provides customers with solutions and decision tools that combine public and industry specific content with advanced technology and analytics to assist them in evaluating and predicting risk and enhancing operational efficiency. The Legal segment is a global provider of legal, regulatory and business information and analytics that helps customers increase productivity, improve decision-making and outcomes and advance the rule of law around the world. The Exhibitions segment is an event business, enhancing the effect of face-to-face through data and digital tools. The Print & print-related segment consistent with financial information provided to the board. The company was founded by Albert Edward Reed in 1903 and is headquartered in London, the United Kingdom.

RELX Plc - ADR

RELX is a focal point of discussion as fears of AI disruption from new legal tools cause a sell-off, while a segment of the community views the dip as a prime opportunity to invest in its high-quality, data-moat business, emphasizing its strong AI integration and ongoing share buyback program.

Lighter is a decentralized trading platform built for unmatched security and scale. It’s the first exchange to offer verifiable order matching and liquidations while delivering best-in-class performance on par with traditional exchanges.

lighter

LIT (Lighter) is trending as investors debate strong bullish catalysts like a new Indodax listing and mandatory staking creating a supply squeeze against community concerns over its reported Coinbase delisting and upcoming rebrand to HEI.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as the community fiercely debates its long-term potential following the rollout of Polkadot 2.0, which introduces Agile Coretime and a new fixed token supply to enhance scarcity and network utility. While many see these fundamental upgrades as a catalyst for a major reversal and increased institutional interest, others remain highly skeptical, citing continued price declines and perceived project setbacks.

Thomson Reuters Corp. engages in the provision of news and information for professional markets. It operates through the following segments: Legal Professionals, Corporates, Tax and Accounting Professionals, Reuters News, and Global Print. The Legal Professionals segment provides research and workflow products to law firms and government. The Corporates segment serves corporate customers with full suite of content-enabled technology solutions for in-house legal, tax, regulatory, compliance, and information technology professionals. The Tax and Accounting Professionals segment offers research and workflow products focusing on intuitive tax offerings and automating tax workflows to tax, accounting, and audit professional in accounting firms. The Reuters News segment supplies business, financial, national, and international news to professionals via desktop terminals. The Global Print segment offers legal and tax information primarily in print format to customers around the world. The company was founded in 1799 and is headquartered in Toronto, Canada.

Thomson-Reuters Corp

Thomson Reuters is experiencing a significant sell-off to new lows, despite reporting robust earnings, a raised dividend, and a strong outlook, as community fears escalate around AI startups like Anthropic disrupting its established professional software and data services, sparking debate over the true defensibility of its proprietary content.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after launching a low-cost compounded weight-loss pill, which immediately drew legal threats from major pharmaceutical companies and prompted a swift FDA response and DOJ referral regarding potential regulatory violations. The community is fiercely debating whether this move is a legitimate disruption challenging "big pharma" or an illegal "copycat" action that could lead to significant penalties and impact the company's long-term viability.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending after its Q3 earnings miss, cautious 2026 outlook citing weak housing demand, and news of corporate job cuts and a full return-to-office, fueling concerns about a "renovation recession." Community discussions are split between bearish sentiment over macroeconomic headwinds and bullish views on its long-term Pro strategy and digital investments creating a "buy the dip" opportunity.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

ALMU is trending as its patented technology for integrating high-performance compound semiconductors on large silicon wafers is gaining significant attention as a game-changer for energy-efficient AI optical interconnects, advanced mobile sensors, and quantum computing. Community chatter focuses on the company's low-float and near-term commercialization pivot, with investors eagerly anticipating strategic partnerships and design wins.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE CRYPTO is garnering significant attention as its strong performance and aggressive token buyback program stand out amidst a volatile market, drawing community focus to upcoming token unlocks and increasing institutional interest for the high-volume decentralized exchange following recent major exchange listings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy Sangiovanni sold 3,000 shares of the company's stock in a transaction dated Tuesday, February 3rd. The shares were sold at an...

Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CEO Neil Mcfarlane sold 91,000 shares of the firm's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock, MarketBeat Ratings...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) saw a significant drop in short interest in January. As of January 15th, there was short interest totaling 3,991,736 shares, a drop of 32.5...

Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher - Here's What Happened

Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher - What's Next...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat reports. One...

Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC

Stonepine Capital Management LLC boosted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 19.3% in the second quarter, according to the company in its most recent Form...

Zevra Therapeutics (NASDAQ:ZVRA) Trading Up 3.8% - Here's Why

Zevra Therapeutics (NASDAQ:ZVRA) Trading Up 3.8% - Should You Buy...

Campbell & CO Investment Adviser LLC Buys Shares of 83,245 Zevra Therapeutics, Inc. $ZVRA

Campbell & CO Investment Adviser LLC purchased a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the second quarter, according to its most recent Form 13F filing with the...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

ZVRA
Zevra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ZVRA News

ZVRAZevra Therapeutics Inc